Is Janux Therapeutics Inc (JANX) overvalued? · rev $10.3M
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
This page asks whether Janux Therapeutics Inc (JANX) looks expensive on cached numbers — not a short thesis.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
JANX currently screens at market cap $1.49B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next JANX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the JANX stock page for the full model, not this heading.
Not investment advice.